Stocktoria
Immunocore Holdings plc IMCR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-02-05
Immunocore Holdings plc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating margin | -11.3% | -22.7% | -23.9% | -29.7% |
| Net margin | -8.9% | -16.5% | -22.2% | -30.1% |
| FCF margin | -3.8% | 6.7% | -1.0% | -29.5% |
| Return on assets | -3.3% | -5.1% | -9.3% | -10.0% |
| Return on equity | -9.3% | -14.2% | -15.0% | -15.5% |
| Current ratio | 4.04 | 4.38 | 3.80 | 4.70 |
| Revenue growth | 29.0% | 24.4% | 43.1% | — |
Source: SEC EDGAR filings · CIK 0001671927 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.